Liaoning Chengda Biotechnology Co Ltd
SSE:688739

Watchlist Manager
Liaoning Chengda Biotechnology Co Ltd Logo
Liaoning Chengda Biotechnology Co Ltd
SSE:688739
Watchlist
Price: 27.7 CNY -3.65% Market Closed
Market Cap: 5.1B CNY
Have any thoughts about
Liaoning Chengda Biotechnology Co Ltd?
Write Note

P/E
Price to Earnings

12.2
Current
10.6
Median
23
Industry
Higher than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
12.2
=
Market Cap
5.1B CNY
/
Net Income
420.3m CNY
All Countries
Close
Earnings Growth
CN
Liaoning Chengda Biotechnology Co Ltd
SSE:688739
Average P/E: 178.5
12.2
-50%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -178 533.6 N/A
US
Abbvie Inc
NYSE:ABBV
59
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -263.9
42%
US
Gilead Sciences Inc
NASDAQ:GILD
910.1
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -478.6 N/A
AU
CSL Ltd
ASX:CSL
33.7
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.8
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.4 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.9 N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
15.1
2-Years Forward
P/E
12.9
3-Years Forward
P/E
22.1

See Also

Discover More